Literature DB >> 11170297

Role of TGF-beta in immune-evasion of cancer.

C Beck1, H Schreiber, D Rowley.   

Abstract

One of the major obstacles in tumor-immunology is the outgrowth of malignant tumors despite their immunogenicity and recognition by the immune-system. Multiple mechanisms for this phenomenon have been proposed. We review the possible involvement of transforming growth factor beta (TGF-beta) in this context. TGF-beta is a cytokine with pleiotropic functions, involved in multiple physiologic processes including immunoregulation. Immune elimination of most cancers ultimately depends on cytolytic T cells (CTL). We propose a mechanism of specific suppression of cytolytic T cell (CTL)-responses mediated through immunoglobulin-bound TGF-beta (IgG-TGF-beta), secreted by activated B cells, and a cell of myeloid origin. This mononuclear "Veto" cell presumably binds IgG-TGF-beta through Fc-receptors and activates latent TGF-beta. The suggestion that B cell responses can inhibit tumor rejection is supported by observations in B cell-deficient mice. Ways for enhancing effective cancer immunity by interfering with the network of interactions involving IgG-TGF-beta are discussed. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170297     DOI: 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  27 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

2.  Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.

Authors:  M Dohadwala; J Luo; L Zhu; Y Lin; G J Dougherty; S Sharma; M Huang; M Pold; R K Batra; S M Dubinett
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

Review 3.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma.

Authors:  Wei Guo; Zhiming Dong; Yanli Guo; Zhifeng Chen; Zhibin Yang; Gang Kuang
Journal:  Mol Biol Rep       Date:  2011-07-22       Impact factor: 2.316

5.  Ki-67, TGF-β1, and elastin content are significantly altered in lip carcinogenesis.

Authors:  Gabriela Salvadori; Jean Nunes Dos Santos; Marco Antonio Trevizani Martins; Artur Cunha Vasconcelos; Luise Meurer; Pantelis Varvaki Rados; Vinicius Coelho Carrard; Manoela Domingues Martins
Journal:  Tumour Biol       Date:  2014-05-06

Review 6.  Metabolic mechanisms of tumor resistance to T cell effector function.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

8.  The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction.

Authors:  Gregory Riedlinger; Jonathan Adams; John R Stehle; Michael J Blanks; Anne M Sanders; Amy M Hicks; Mark C Willingham; Zheng Cui
Journal:  BMC Cancer       Date:  2010-05-03       Impact factor: 4.430

9.  Immunoregulation through IL-10 gene expression and the fate of cytotoxic T lymphocyte-mediated tumor immunotherapy.

Authors:  Nitya G Chakraborty
Journal:  Indian J Hum Genet       Date:  2009-01

Review 10.  Immune system: a double-edged sword in cancer.

Authors:  Bodduluru Lakshmi Narendra; Kasala Eshvendar Reddy; Saladi Shantikumar; Sistla Ramakrishna
Journal:  Inflamm Res       Date:  2013-07-19       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.